KRAS and cancer: The gene projections generated for each cancer type show that most of the co-occurring TP53 and KRAS pairs are in pancreatic cancer, as shown in Figure 11A and Supplementary Table S7, suggesting their importance in driving pancreatic cancer (Kim et al., 2021) and highlighting that both mutations are likely required for metastasis on these tumors.